Breaking News Instant updates and real-time market news.

ONTX

Onconova

$0.14

(0.00%)

13:19
11/26/19
11/26
13:19
11/26/19
13:19

Onconova downgraded to Hold from Buy at Maxim

Maxim analyst Jason McCarthy downgraded Onconova to Hold from Buy.

ONTX Onconova
$0.14

(0.00%)

12/03/18
12/03/18
NO CHANGE

Onconova presents rigosertib with azacitidine data at ASH
Onconova Therapeutics announced the presentation of the efficacy and safety results of oral rigosertib in combination with azacitidine in patients with HR-MDS reported at an oral presentation during the American Society of Hematology, or ASH. Rigosertib, the company's lead compound, is being evaluated in both intravenous and oral forms. Seventy-four patients were treated with a median age of 69 years at nine clinical sites and received either 840 mg or 1,120 mg of oral rigosertib daily divided into two doses, in combination with a standard dose of injectable azacitidine. Of the 55 evaluable patients, 29 patients were treated with a daily dose of 1,120 mg of oral rigosertib, either 560 mg twice daily or 840 mg in the a.m. and 280 mg in the afternoon. Twenty-six patients were treated with 560 mg in the AM and 280 mg in the PM for the first three weeks of a four-week cycle. All patients also received 75 mg/m2/day SC or IV azacitidine during the second week of the four-week cycle. The median duration of treatment for the HMA naive and HMA failed patients was 7.8 and 4.9 months respectively. The median duration of response in these groups was 12.2 and 10.8 months, respectively. The overall response rate, or ORR, using the IWG 2006 criteria, in 29 HMA naive patients was 90%, including 10 patients with complete remission, or CR. Among the 26 evaluable HMA-failed patients the ORR was 54% including 8% CR or PR. The median time to initial and best response were 1 and 4 cycles in the HMA naive group and 2 and 5 cycles in the HMA failed group. The safety population received at least 1 dose of oral rigosertib. The combination was well tolerated. Other than genitourinary adverse events, or AEs, the AE profile was similar to those described for azacitidine alone in this patient population. Genitourinary AEs, including hematuria and dysuria were observed. A safety optimization strategy was implemented for the higher dose cohort of 1,120 mg of oral rigosertib. These strategies included earlier in the day administration of the PM dose, oral hydration, monitoring of urinary pH and mandatory bladder emptying at night. Collectively these strategies resulted in mitigation of the target genitourinary AEs, including reduction of genitourinary grade 3 AEs reported from an earlier cohort despite receiving a higher dose of oral rigosertib. In conclusion, oral rigosertib in combination with azacitidine was well tolerated in HMA naive and HMA failed HR-MDS patients. The combination produced an encouraging rate of overall response and complete remission in both groups. The safety optimization strategies and increased dose exploration of oral rigosertib in the combination is leading to the development of a pivotal Phase 3 trial in HMA and chemotherapy naive patients. Onconova plans to meet with the FDA to discuss the results of the Phase 2 trial and the planned Phase 3 trial, and to seek a special protocol assessment. The company has partnered rigosertib with SymBio Pharmaceuticals, for Japan and Korea, and with Pint Pharma for Latin American countries. Both partners have indicated their interest in participating in the proposed new pivotal Phase 3 trial by enrolling patients in their respective territories. SymBio is currently conducting Phase 1 studies with oral rigosertib in Japan and also participating in the Phase 3 global INSPIRE trial. The company is also actively seeking additional collaborations for rigosertib in other geographies.
07/25/19
NBLE
07/25/19
INITIATION
Target $12
NBLE
Outperform
Onconova initiated with an Outperform at Noble Capital
Noble Capital analyst Ahu Demir initiated Onconova with an Outperform rating and $12 price target, noting that the company's Phase 3 INSPIRE study of rigosertib in patients with high-risk myelodysplastic syndrome is expected to have a data readout in 2020. While the company's main focus is MDS, Demir sees it having promising early stage opportunities beyond MDS, he noted. He believes the current stock price does not reflect the potential of Onconova's pipeline, Demir added.
07/25/19
07/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. FleetCor (FLT) initiated with a Neutral at Baird. 2. Medifast (MED) initiated with a Buy at Jefferies. 3. EnLink Midstream (ENLC) initiated with a Neutral at Mizuho. 4. Onconova (ONTX) initiated with an Outperform at Noble Capital. 5. Gold Standard Ventures (GSV) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

DHR

Danaher

$147.51

-0.66 (-0.45%)

, PCG

PG&E

$11.05

1.4 (14.51%)

08:55
12/10/19
12/10
08:55
12/10/19
08:55
Options
Notable open interest changes for December 10th »

Monday's total…

DHR

Danaher

$147.51

-0.66 (-0.45%)

PCG

PG&E

$11.05

1.4 (14.51%)

AAPL

Apple

$266.93

-3.75 (-1.39%)

AMD

AMD

$38.91

-0.7 (-1.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 07

    Jan

08:55
12/10/19
12/10
08:55
12/10/19
08:55
General news
The U.S. productivity report »

The U.S. productivity…

MDB

MongoDB

$131.03

-0.19 (-0.14%)

08:54
12/10/19
12/10
08:54
12/10/19
08:54
Recommendations
MongoDB analyst commentary  »

MongoDB price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 18

    Dec

AMZN

Amazon.com

$1,749.61

-1.18 (-0.07%)

, TGT

Target

$126.43

1.4 (1.12%)

08:54
12/10/19
12/10
08:54
12/10/19
08:54
Recommendations
Amazon.com, Target, Walmart analyst commentary  »

Amazon one-day offerings…

AMZN

Amazon.com

$1,749.61

-1.18 (-0.07%)

TGT

Target

$126.43

1.4 (1.12%)

WMT

Walmart

$119.34

-0.43 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFRX

ContraFect

$0.30

-0.038 (-11.41%)

08:50
12/10/19
12/10
08:50
12/10/19
08:50
Syndicate
ContraFect 37.15M share Spot Secondary priced at 27c »

acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:50
12/10/19
12/10
08:50
12/10/19
08:50
General news
U.S. Q3 productivity was revised up to a -0.2% rate »

U.S. Q3 productivity was…

08:50
12/10/19
12/10
08:50
12/10/19
08:50
General news
FX Action: The dollar »

FX Action: The dollar…

ROAD

Construction Partners

$20.56

0.66 (3.32%)

08:49
12/10/19
12/10
08:49
12/10/19
08:49
Recommendations
Construction Partners analyst commentary  »

Construction Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

OPRX

OptimizeRx

$10.35

1.26 (13.86%)

08:48
12/10/19
12/10
08:48
12/10/19
08:48
Recommendations
OptimizeRx analyst commentary  »

OptimizeRx named a top…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

KALV

KalVista

$15.28

0.92 (6.41%)

08:48
12/10/19
12/10
08:48
12/10/19
08:48
Recommendations
KalVista analyst commentary  »

KalVista price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CONN

Conn's

$20.51

1.08 (5.56%)

08:47
12/10/19
12/10
08:47
12/10/19
08:47
Conference/Events
Conn's management to meet with Oppenheimer »

Dinner Meeting to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

QSR

Restaurant Brands

$66.00

0.155 (0.24%)

, DNKN

Dunkin' Brands

$76.23

-0.39 (-0.51%)

08:47
12/10/19
12/10
08:47
12/10/19
08:47
Recommendations
Restaurant Brands, Dunkin' Brands, Del Taco, Noodles & Company analyst commentary  »

Burger King, Dunkin, Del…

QSR

Restaurant Brands

$66.00

0.155 (0.24%)

DNKN

Dunkin' Brands

$76.23

-0.39 (-0.51%)

TACO

Del Taco

$7.38

0.1 (1.37%)

NDLS

Noodles & Company

$5.80

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHDN

Churchill Downs

$131.32

-0.1 (-0.08%)

08:46
12/10/19
12/10
08:46
12/10/19
08:46
Conference/Events
Churchill Downs management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CNST

Constellation Pharmaceuticals

$36.15

-7.95 (-18.03%)

08:45
12/10/19
12/10
08:45
12/10/19
08:45
Recommendations
Constellation Pharmaceuticals analyst commentary  »

Constellation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

GME

GameStop

$6.32

-0.34 (-5.11%)

, NVAX

Novavax

$4.16

-0.18 (-4.15%)

08:45
12/10/19
12/10
08:45
12/10/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

GME

GameStop

$6.32

-0.34 (-5.11%)

NVAX

Novavax

$4.16

-0.18 (-4.15%)

CRWD

Crowdstrike

$49.00

-1.89 (-3.71%)

BBBY

Bed Bath & Beyond

$15.42

0.65 (4.40%)

CGC

Canopy Growth

$21.26

2.61 (13.99%)

HEXO

Hexo

$2.29

0.195 (9.31%)

OSTK

Overstock.com

$7.19

-0.17 (-2.31%)

SVXY

ProShares Short VIX Short-Term Futures

$60.81

-1.61 (-2.58%)

TQQQ

ProShares UltraPro QQQ

$76.38

-0.96 (-1.24%)

PAGP

Plains GP Holdings

$17.61

0.25 (1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 13

    Dec

  • 16

    Dec

  • 08

    Jan

  • 09

    Dec

BECN

Beacon Roofing

$28.96

-0.13 (-0.45%)

08:43
12/10/19
12/10
08:43
12/10/19
08:43
Conference/Events
Beacon Roofing management to meet with Seaport Global »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 18

    Dec

  • 19

    Dec

DY

Dycom

$46.37

-4.565 (-8.96%)

08:42
12/10/19
12/10
08:42
12/10/19
08:42
Recommendations
Dycom analyst commentary  »

Dycom selloff after note…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

THO

Thor Industries

$64.28

-3.485 (-5.14%)

08:41
12/10/19
12/10
08:41
12/10/19
08:41
Recommendations
Thor Industries analyst commentary  »

Thor Industries price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

NWE

NorthWestern

$71.27

-0.57 (-0.79%)

08:41
12/10/19
12/10
08:41
12/10/19
08:41
Earnings
NorthWestern backs FY19 adjusted EPS view $3.38-$3.48, consensus $3.42 »

Sees FY20 adjusted EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SPY

SPDR S&P 500 ETF Trust

$313.89

-0.93 (-0.30%)

, SPX

S&P 500

$0.00

(0.00%)

08:40
12/10/19
12/10
08:40
12/10/19
08:40
Periodicals
U.S. and China negotiators planning for delay of Dec. 15 tariffs, WSJ says »

U.S. and Chinese trade…

SPY

SPDR S&P 500 ETF Trust

$313.89

-0.93 (-0.30%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:40
12/10/19
12/10
08:40
12/10/19
08:40
General news
Breaking General news story  »

Week of 12/7 Redbook to…

08:40
12/10/19
12/10
08:40
12/10/19
08:40
General news
Breaking General news story  »

Week of 12/7 Redbook to…

ALMFF

Altium

$0.00

(0.00%)

08:39
12/10/19
12/10
08:39
12/10/19
08:39
Initiation
Altium initiated  »

Altium initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$42.37

0.22 (0.52%)

08:38
12/10/19
12/10
08:38
12/10/19
08:38
Hot Stocks
Breaking Hot Stocks news story on Aecom »

Aecom sees FY21 adj.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

BCOV

Brightcove

$9.21

-0.11 (-1.18%)

08:38
12/10/19
12/10
08:38
12/10/19
08:38
Conference/Events
Brightcove management to meet with Northland »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.